Isotechnika Pharma Inc.
Isotechnika Terminates Existing Agreement With ILJIN
Isotechnika Pharma Inc. 31.01.2012 14:15 --------------------------------------------------------------------------- Company Secures Rights and Seeks More Favourable License Agreement EDMONTON, Alberta, 2012-01-31 14:15 CET (GLOBE NEWSWIRE) -- Consistent with prior communications from ILJIN, the company is pursuing discussions with ILJIN Life Science Co., Ltd. ('ILJIN') to potentially change the current relationship with ILJIN in order to better advance the voclosporin program. The company has therefore chosen to exercise its right to terminate the existing Development, Distribution and License Agreement (the 'DDL') with ILJIN. In doing so, Isotechnika secures full rights to voclosporin for transplant and autoimmune indications in the United States and other regions outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. The company already owns full rights in Europe. 'In order to have more meaningful discussions with ILJIN, it was determined that the current contract was not appropriate. Terminating the existing agreement frees the company to engage ILJIN, as well as other companies who have expressed interest in voclosporin,' commented Dr. Robert Foster, Isotechnika's CEO. 'This action has given the company the opportunity to secure a new, more favourable, relationship to effectively bring voclosporin to the market.' About Isotechnika Pharma Inc Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics designed to offer key safety advantages over currently available treatments. Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated US$3.0 billion market for this class of immunosuppressants. Isotechnika Pharma Inc. trades on the Toronto Stock Exchange under the symbol 'ISA'. More information on Isotechnika Pharma can be found at www.isotechnika.com or www.sedar.com. We seek Safe Harbour. CONTACT: Dr. Robert Foster Chairman & CEO 780-487-1600 (x247) rfoster@isotechnika.com Dr. Launa Aspeslet Chief Operating Officer 780-487-1600 (x225) laspeslet@isotechnika.com Leonard Zehr Managing Director Kilmer Lucas Inc. 905-906-6908 leonard@kilmerlucas.com News Source: NASDAQ OMX 31.01.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Isotechnika Pharma Inc. Canada Phone: Fax: E-mail: Internet: ISIN: CA46500A1057 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found